A scientific research institute with expertise in the design and conduct of early phase clinical studies for new therapies and devices in diabetes, obesity and other metabolic disorders. We handle the complex challenges of first dose in human, safety, tolerability, PK, and PD diabetes projects. We specialize in a rate technique called the "automated glucose clamp". This methodology is used to determine the time-action profile of new blood glucose-lowering compounds and to evaluate their impact on insulin sensitivity and compartment specific glucose turnover. Our cardiometabolic capabilities entimely assessment of cardiovascular side effects.